Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2022 08:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results

CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
March 30, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
March 22, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference

Abstracts Review Positive In vivo Data and the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen...
March 15, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program

CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
February 22, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders

CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
February 15, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference

Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New Orleans CARLSBAD, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...
February 01, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302

Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
January 18, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics

Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
December 14, 2021 09:18 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Promotes Amy Broidrick to President

Ms. Broidrick to retain title of Chief Strategy Officer CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on...
December 01, 2021 15:25 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering

CARLSBAD, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain...